Abstract:Microglia as an important type of innate immune cell in the brain have been considered as an effective therapeutic target for the treatment of central nervous degenerative diseases. Herein, we report cell membrane coated novel biomimetic Cu<sub>2–<i>x</i></sub>Se-PVP-Qe nanoparticles (denoted as nanoparticles, where PVP is poly(vinylpyrrolidone), Qe is quercetin, and CM is the cell membrane of neuron cells) for effectively targeting and modulating microglia to treat Parkinson's disease (PD). The CSPQ nanoparticles exhibit multienzyme activities and could effectively scavenge the reactive oxygen species and promote the polarization of microglia into the anti-inflammatory M2-like phenotype to relieve neuroinflammation. We reveal that biomimetic nanoparticles targeted microglia through the specific interactions between the membrane surface vascular cells adhering to molecule-1 and α4β1 integrin expressed by microglia. They could significantly improve the symptoms of PD mice to result in an excellent therapeutic efficacy, as evidenced by the recovery of their dopamine level in cerebrospinal fluid, tyrosine hydroxylase, and ionized calcium binding adapter protein 1 to normal levels. Our work demonstrates the great potential of these robust biomimetic nanoparticles in the targeted treatment of PD and other central nervous degenerative diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/jacs.0c09390?goto=supporting-info">https://pubs.acs.org/doi/10.1021/jacs.0c09390</a>.Additional information including materials, synthesis, and characterization assay of enzymatic activity and ROS scavenging capacity of QP complex, CSP, and CSPQ nanoparticles (TEM, particle size distribution, TGA, ESR, reaction mechanism of enzyme activity detection; ζ potential; CLSM images and FCAS of intracellular ROS level); immunofluorescence staining of β1 integrins in BV2 cells; PA images and signals intensities of the brain after intravenous injection with nanoparticles; photograph of brain slice stained with rubeanic acid; H&E images of major organs (<a class="ext-link" href="/doi/suppl/10.1021/jacs.0c09390/suppl_file/ja0c09390_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Ameliorating Mitochondrial Dysfunction of Neurons by Biomimetic Targeting Nanoparticles Mediated Mitochondrial Biogenesis to Boost the Therapy of Parkinson's Disease

Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson's Disease

Boosting Neurite Outgrowth and Anti-Oxidative Stress for Treatment of Parkinson's Disease by Biomimetic Ultrasmall Nanoparticles

Targeting mitochondria with small molecules: A promising strategy for combating Parkinson's disease

A Novel Nanoparticle System Targeting Damaged Mitochondria for the Treatment of Parkinson's Disease

Targeting Microglia for Therapy of Parkinson’s Disease by Using Biomimetic Ultrasmall Nanoparticles

Regulation of mitophagy and mitochondrial function: Natural compounds as potential therapeutic strategies for Parkinson's disease

Targeting the Pathogenesis and Boosting the Therapeutic Efficacy of Parkinson's Disease by Advanced Nanoparticles

Engineered Inhalable Nanocatalytic Therapeutics for Parkinson's Disease by Inducing Mitochondrial Autophagy

Mitochondrial homeostasis regulation: A promising therapeutic target for Parkinson's disease

Mitochondrial‐Targeting Vitamin B <sub>3</sub> Ameliorates the Phenotypes of Parkinson's Disease in vitro and in vivo by Restoring Mitochondrial Function

Facilitating Pro-survival Mitophagy for Alleviating Parkinson's Disease Via Sequence-Targeted Lycopene Nanodots.

Mitochondrial transplantation exhibits neuroprotective effects and improves behavioral deficits in an animal model of Parkinson's disease

Near-Infrared Radiation-Assisted Drug Delivery Nanoplatform to Realize Blood–Brain Barrier Crossing and Protection for Parkinsonian Therapy

Mitochondrial Dysfunction and Parkinson’s Disease—Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy

Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities

Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3β/PP2A pathway in Parkinson's disease

Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinson’s Disease

Plant-derived Exosomes As Cell Homogeneous Nanoplatforms for Brain Biomacromolecules Delivery Ameliorate Mitochondrial Dysfunction Against Parkinson’s Disease

Microfluidics-enabled mesenchymal stem cell derived Neuron like cell membrane coated nanoparticles inhibit inflammation and apoptosis for Parkinson's Disease

A Dual Synergetic Nanoreactor for Managing Parkinson's Disease by Regulating Inflammation and Mitigating Oxidative Damage